Forty six prepubertal boys who had constitutional growth delay were treated with oxandrolone. Mean age at the onset of treatment was 11-9 years (range 9-0-14-0) and bone age delay was 1-9 'years'. The dose of oxandrolone used was a mean of 0.05 mg/kg (range 0-03-0-18) for a mean of 0-9 years (range 0.2-3.6). Height velocity increased from a mean (SD) before treatment of 4-0 (1-0) to 7-5 (1-2) cm/year with oxandrolone. Growth rate was sustained at 7-6 (2.2) cm/year in the period after treatment. Those boys who attained a testicular volume of 4 ml or greater at the end of the treatment period had the most pronounced sustained growth acceleration. Height for bone age SD score did not alter significantly from a mean of -1-0 before treatment to -1-2 after treatment.
(range 0.2-3.6). Height velocity increased from a mean (SD) before treatment of 4-0 (1-0) to (1-2) cm/year with oxandrolone. Growth rate was sustained at 7-6 (2.2) cm/year in the period after treatment. Those boys who attained a testicular volume of 4 ml or greater at the end of the treatment period had the most pronounced sustained growth acceleration. Height for bone age SD score did not alter significantly from a mean of -1-0 before treatment to -1-2 after treatment.
Oxandrolone is a safe and effective treatment for prepubertal boys with constitutional growth delay.
Oxandrolone is an anabolic steroid that is effective in a low dose regimen for the treatment of constitutional delay of growth and puberty.' This is not a placebo effect2 and does not decrease final height. 3 For psychological reasons such children may require treatment to improve their short term growth rate at an earlier stage of sexual maturation than would be expected for the spontaneous growth spurt of puberty. 1 Treatment alters the 'tempo' of their growth without altering final height prognosis. 1 By definition, constitutional delay of growth and puberty requires short stature, delay of epiphyseal maturation, and pubertal delay (>2 SD). However, children who will progress to develop constitutional delay of growth and puberty can often be predicted at a much earlier age by their pattern of bone age maturation and growth delay (which we have described as constitutional growth delay). We believe it is important to treat such children at an 
Chronological age at onset of treatment (years) 11-9 (9-0 to 14-0) Duration of period (years) 0-8 (0-2 to 3-3) 0 9 (0-2 to 3 6) 0-8 (0-2 to 1 8) Bone age delay (years) -1 9 (-52 to -0-1) Time from start of treatment to onset of puberty (years) 0-8 (0 25 to 3-6) Height SD score for bone age -1-0 (-3 0 to +1 (1 2) cm/year, which was significant to a level of p<0O001. Forty of the boys entered puberty during the treatment period and these boys tended to grow at a faster rate than the six who remained prepubertal (fig 1) . In the period after treatment the growth rate was sustained at a mean of 7-6 (2 2) cm/year. Three boys failed to enter puberty in the period after treatment. Three boys failed follow up during the period after treatment, all of whom had achieved a testicular volume of 4 ml or greater at the end of the treatment period. From correspondence with the parents we believe that the reason for non-attendence was satisfaction with their growth. Five boys required further courses of treatment, four for inadequately sustained growth rate who were treated with a repeat course of oxandrolone and one who was given depotestosterone injections to advance virilisation.
Boys who remained at a testicular volume of less than 4 ml achieved a lower rate of growth during oxandrolone treatment than those who achieved 4 ml or greater (fig 1) . The degree of sexual maturation achieved appeared particularly important during the period after treatment and a sustained growth rate of >6-4 cm/year was achieved only in boys who had achieved a testicular volume of 4 ml or greater. Eventually the growth acceleration induced by oxandrolone became indistinguishable from the spontaneous growth spurt of puberty at the attainment of a 10 ml testicular volume (fig 2) .
Despite administration of an exogenous androgen the rate of progression of genital stage was indistinguishable from that of normal puberty (fig 3) . Moreover the pattern of puberty and the harmony between the acquisition of genital stage, pubic hair stage, and testicular volume was similar to that of normal boys ( fig  2) .
Although there was a decrease in height for bone age SD score from a mean of -1-0 in the period before treatment to -1 2 in the period after treatment (table) this was not significant (p>0 5). One boy was treated with low dose oxandrolone for 3-6 years and demonstrated an appropriate advance in his epiphyseal maturation. None of the boys experienced adverse reactions during their course of treatment.
Discussion
Oxandrolone in prepuberty caused an effective increase in growth rate that was at a higher level in those boys who entered puberty during their course of oxandrolone treatment. Normal boys would not expect the commencement of their growth spurt to be until the attainment of 10 ml testicular volume (genitalia stage 3-4). 14 Oxandrolone treatment brought forward the timing of the growth acceleration, which was sustained in the post-treatment period, while allowing a normal pattern and rate of pubertal maturation. This was of therapeutic value to the boys as the treatment anticipated the growth deceleration that would have occurred as well as their probable late timing of the spontaneous growth spurt.'5 Boys with constitutional delay may experience enormous psychological difficulties associated with their delayed puberty and growth.7 In our group of patients the latter was effectively treated, anticipating the former.
There was no significant decrease in height for bone age SD score. Our data suggest that such a prolonged course of oxandrolone (mean duration almost one year) does not alter final height prognosis and that such treatment enables boys to achieve their expected final height at an earlier age. Indeed one boy was treated with low dose oxandrolone for 3-6 years without a reduction in final height prognosis.
We propose that when it is possible to diagnose constitutional growth delay in a boy who will almost certainly develop delayed puberty then a prolonged course of low dose oxandrolone is an effective treatment regimen. This may allow an earlier growth acceleration and hopefully achieve a height within the normal range at such a critical time for emotional, educational, as well as physical development. Certainly we do not believe that this form of treatment leads to any decrease in final height attainment. The cessation of treatment should be at the attainment of a testicular volume of 4 ml or greater, at which time the growth spurt induced by low dose oxandrolone treatment should be sustained.
Although short courses of oxandrolone are effective in the treatment of constitutional delay of growth and puberty,' prolonged courses of oxandrolone, for about one year, are required in prepubertal boys with constitutionally delayed growth. Such longer courses do not lead to adverse side effects, as indeed such prolonged courses appear to be safe when used in girls with Turner's syndrome.'6 An alternative treatment regimen would be to use depot or oral testosterone preparations. The latter are irregularly absorbed from the gastrointestinal tract and the former may lead to a rapid induction of secondary sexual characteristics as well as an induced growth acceleration. In our experience the psychological benefits of a prolonged course of oxandrolone are significant and such treatment regimens are safe and effective. 
